David Queiroz Borges Muniz

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Thomas Powles, Piotr Tomczak, Se Hoon Park et al. · The Lancet Oncology · 2022 · 278 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Acquired Lipodystrophy Associated With Nivolumab in a Patient With Advanced Renal Cell Carcinoma

Camila Kruschewsky Falcão, Marina C. Cabral, José Maurício Mota et al. · The Journal of Clinical Endocrinology & Metabolism · 2019 · 52 citations · Full text

Medicine, Endocrinology, Oncology +13

A phase II trial of pembrolizumab plus platinum-based chemotherapy as first-line systemic therapy in advanced penile cancer: HERCULES (LACOG 0218) trial.

Fernando Cotait Maluf, Karine Martins da Trindade, Daniel D’Almeida Preto et al. · Journal of Clinical Oncology · 2024 · 25 citations · Full text

Medicine, Oncology, Pharmacology +17

Neutrophil-to-Lymphocyte Ratio Predicts Cancer Outcome in Locally Advanced Clear Renal Cell Carcinoma

Maurício Cordeiro, Eder Nisi Ilário, Daniel Kanda Abe et al. · Clinical Genitourinary Cancer · 2021 · 23 citations

Medicine, Immunology, Oncology +12

The LACOG-0415 phase II trial: abiraterone acetate and ADT versus apalutamide versus abiraterone acetate and apalutamide in patients with advanced prostate cancer with non-castration testosterone levels

Gustavo Werutsky, Fernando Cotait Maluf, Eduardo Cronemberger et al. · BMC Cancer · 2019 · 17 citations · Full text

Medicine, Oncology, Urology +17